MBX Biosciences (MBX) Other Accumulated Expenses (2023 - 2026)

MBX Biosciences (MBX) has 4 years of Other Accumulated Expenses data on file, last reported at $294000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses fell 93.68% year-over-year to $294000.0; the trailing twelve-month figure through Mar 2026 stood at $294000.0 (down 93.68% YoY), and the FY2025 full-year result was $7.4 million, up 141.72% from the prior year.
• Other Accumulated Expenses fell to $294000.0 in Q1 2026, from $7.4 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $7.4 million in Q4 2025 to a low of $114000.0 in Q4 2023.
• A 4-year average of $2.5 million and a median of $1.8 million in 2024 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses jumped 2586.84% in 2024 and tumbled 93.68% in 2026, its largest moves.
• Tracing MBX's Other Accumulated Expenses over 4 years: stood at $114000.0 in 2023, then jumped by 2586.84% to $3.1 million in 2024, then surged by 141.72% to $7.4 million in 2025, then plunged by 96.03% to $294000.0 in 2026.
• Business Quant data shows MBX's Other Accumulated Expenses at $294000.0 in Q1 2026, $7.4 million in Q4 2025, and $572000.0 in Q3 2025.